ELISA

Microbial Transglutaminase (MTG) ELISA


ELISA for the detection of Microbial Transglutaminase (MTG)

Order
Quantity
Price
Status
1 Kit 365 € available


Documents
Art. No. E021
Background info The present kit (E021) is a sandwich enzyme-linked immunosorbent assay (ELISA) for the detection and quantitative determination of Microbial Transglutaminase from Streptomyces mobaraensis (MTG) in various samples including food samples like meat, sausage, yoghurt, quark, cheese and others.
MTG catalyses the modification of proteins by inserting an isopeptide bond within or between polypeptide chains. Due to this activity MTG is often used for food processing in order to modify properties like texture or taste.
The detection of MTG with the present kit requires sample preparation which includes homogenization and centrifugation.
Quantification of MTG in samples is possible using a calibration curve based on the MTG-standards included in the kit.
Lower MTG-Detection Limit: 0.6 ng/mL (LDL)
Limit of MTG-Quantitation: 3.0 ng/mL (LoQ), 3 ppb (1 mL = 1 g)

MTG ELISA
Assay principle The microtiter plate wells (solid phase) are coated with antibodies specific to microbial transglutaminase.
1st reaction: Microbial transglutaminase present in the sample binds to the immobilised antibodies, forming the antibody-antigen-complex.
2nd reaction: A microbial transglutaminase specific antibody labeled with biotin binds to the antibody-antigen-complex forming an antibody-antigen-[antibody-biotin] sandwich.
3rd reaction: Streptavidin conjugated to horseradish peroxidase (HRP) binds to the biotin-label fo the antibody-antigen-[antibody-biotin] sandwich.
4th reaction: The HRP-labeled complex converts a substrate (TMB) into a blue product which upon addition of the stop solution turns yellow. Samples containing microbial transglutaminase develop the blue colour (which upon addition of the stop solution turns yellow), whereas samples without microbial transglutaminase remain colourless.
Reagents in the kit Microtiter plate packed in a resealable foil laminate pouch with a dessicant bag
Sample buffer
Wash buffer
MTG-standard.
Purified anti-microbial transglutaminase antibody labeled with biotin (MTG-Ab conjugate)
Streptavidin-HRP conjugate
Substrate solution
Stop solution (0.5 M H2SO4)
Directions for use
Storage Store the whole kit at 6 - 8°C. It is important that the MTG-standard is not stored below 6°C. The kit is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date. After opening the pouch keep unused microtiter wells resealed to minimize exposure to moisture.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Team-Assistenz (w/m/d) in Teilzeit gesucht
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 27th ISTH Congress

    06.07.2019 - 10.07.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • European Congress on Thrombosis and Haemostasis

    02.10.2019 - 04.10.2019
    Glasgow, United Kingdom

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA